Salvage Hypofractionated Radiotherapy in Combination with Bevacizumab in Patients with Recurrent High Grade Glioma: A Mono-institutional Experience

Publisher： Bentham Science Publishers

E-ISSN： 2212-6988|4|2|145-149

ISSN： 2212-697x

Source： Clinical Cancer Drugs, Vol.4, Iss.2, 2018-01, pp. : 145-149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vitespen, an investigational cancer vaccine, appears to be beneficial for treating patients with recurrent high-grade glioma

By  

Inpharma, Vol. 1, Iss. 1667, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Targeting ErbB Receptors in High-Grade Glioma

By  

Current Pharmaceutical Design, Vol. 17, Iss. 23, 2011-08 ,pp. : 2468-2487

Bentham Science Publishers

Access to resources Recommend Favorite

Current and future directions for Phase II trials in high-grade glioma

By Alexander Brian M   Lee Eudocia Q   Reardon David A   Wen Patrick Y  

Expert Review of Neurotherapeutics, Vol. 13, Iss. 4, 2013-04 ,pp. : 369-387

Informa Healthcare

Access to resources Recommend Favorite

Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future

By Cavaliere Robert   Newton Herbert  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 6, 2006-04 ,pp. : 749-765

Informa Healthcare

Access to resources Recommend Favorite

Carmustine-impregnated wafers and their impact in the management of high-grade glioma

By La Rocca Renato V   Rezazadeh Arash  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1325-1332

Informa Healthcare

Access to resources Recommend Favorite